公 华福证券 司 研 究 固生堂（02273.HK） 2024 年报点评：业绩增长强劲，整体符合预期 公 事件：公司公布 2024 年报，报告期内公司实现收入 30.2 亿元（+30.1%）， 归母净利润 3.07 亿元（+21.6%），经调净利润 4 亿元（+31.4%），整体符 合预期。 其中，24H2 实现收入 16.6 亿元（+24%），经调净利润 2.52 亿元（+24.4%）。 线下业务持续高速增长，业务量价齐升。 司 财 报 点 评 2024 年公司线下业务实现收入 27.4 亿元（+34.5%），我们认为主要系 新收购机构和现有机构业务增长贡献；线上实现收入 2.82 亿元（-1.5%）。 报告期内，公司实现就诊人次 541.1 万人次（+25.9%），实现客单价 559 元（+3.3%），客户回头率由 23 年的 65.2%提升至 24 年的 67.1%。 财务分析：盈利能力持续增强，费用率控制得当。 2024 年公司销售/管理/财务费用率分别为 12.2%/6.1%/0.6%，分别同比 变化+0.1/-0.6/-0.5pct，实现毛利率 30.1%，同比持平，实现归母净利率 10.2% （ ...

Investment Rating - The investment rating for the company is "Outperform the Market" [3] Core Views - The company is expected to achieve steady growth with a significant reduction in net losses, driven by strong performance in its core business and the introduction of new product lines [7][8] - The establishment of Paradigm Group marks a strategic shift towards a dual business model focusing on both B2B and B2C markets, with the consumer electronics segment anticipated to become a key growth driver [7][8] Financial Performance and Forecast - Revenue is projected to grow from 42.04 billion in 2023 to 66.01 billion in 2025, reflecting a year-on-year growth of 25% [7] - The net profit is expected to turn positive by 2025, with a forecasted net profit of 0.49 billion, following a significant reduction in losses from 9.09 billion in 2023 to 0.27 billion in 2024 [7] - The gross margin is expected to stabilize around 44% in 2025, with a gradual increase to 47% by 2027 [7] Business Segments and Growth Drivers - The AI platform business, particularly the "Xianzhi AI Platform," has shown exceptional growth, with revenues increasing by 46.7% in 2024 [7] - The company is focusing on expanding its customer base and enhancing service depth, with benchmark users averaging revenue close to 19.1 million [7] - The consumer electronics segment, Phancy, aims to provide AI-integrated hardware and software solutions, leveraging the company's proprietary AI capabilities [7][8] Strategic Initiatives - The company is heavily investing in R&D, with expenses reaching 2.17 billion in 2024, representing 41.2% of revenue [7] - The launch of the ModelHubAIoT solution is expected to facilitate the deployment of AI models on edge devices, addressing privacy and real-time needs [8] - Collaboration with major partners like Huawei to develop integrated AI solutions is anticipated to enhance product offerings and market reach [8] Valuation and Price Target - The company is valued at a price-to-sales ratio of 5-6 times for 2025, with a target price range of 71.66 to 85.99 HKD [8]

Investment Rating - The report maintains a "Strong Buy" rating for the company, with a target price of HKD 43.90 [1][8]. Core Insights - The company reported a revenue of HKD 2.06 billion for 2024, representing a year-on-year increase of 17.1%, and a net profit of HKD 428 million, up 31.0% year-on-year [1][8]. - The growth in revenue and profit is attributed to increased customer orders and the appreciation of the US dollar [8]. - The company has a diversified product line with significant growth in functional lenses, which achieved revenue of HKD 760 million, a 32.4% increase year-on-year [8]. - The company is actively expanding into the smart glasses market, collaborating with leading consumer electronics firms, which is expected to drive future growth [8]. Financial Summary - For 2024, the company achieved a gross margin of 38.6%, an increase of 1.2 percentage points year-on-year, and a net profit margin of 20.8%, up 2.2 percentage points year-on-year [8][10]. - The company’s revenue is projected to grow to HKD 2.57 billion in 2025, with a year-on-year growth rate of 24.6% [3][11]. - The forecasted net profit for 2025 is HKD 547 million, reflecting a growth rate of 27.6% [3][10]. - The company’s earnings per share (EPS) is expected to increase from HKD 1.00 in 2024 to HKD 1.14 in 2025 [3][10]. Product and Market Performance - The revenue breakdown for 2024 shows that functional lenses accounted for 36.6% of total revenue, standard lenses 44.0%, and custom lenses 19.2% [8]. - The company’s sales volume reached 180 million pieces in 2024, a 12.1% increase year-on-year, with an average selling price of HKD 11.6 per piece [8]. - Revenue by region indicates strong performance in mainland China, the Americas, and Asia (excluding mainland China), with year-on-year growth rates of 13.9%, 16.9%, and 37.9% respectively [8].

[Table_MainInfo] 公司研究/信息服务/计算机 证券研究报告 万国数据-SW（9698）公司研究报告 2025 年 04 月 02 日 [Table_InvestInfo] 投资评级 优于大市 维持 股票数据 | 4[Table_StockInfo 月 1 日收盘价（港元）] | 24.55 | | --- | --- | | 52 周股价波动（港元） | 5.66-48.30 | | 总股本/流通 H 股（百万股） | 1524/1469 | | 总市值/流通市值（百万元） | 37425/36060 | Email:ym13254@haitong.com 相关研究 [Table_ReportInfo] 《国内 IDC 龙头企业，海外业务高速成长》 20250125 市场表现 [Table_QuoteInfo] 沪深 300 对比 1M 2M 3M | 绝对涨幅（%） | -37.28 | 19.14 | 32.31 | | --- | --- | --- | --- | | 相对涨幅（%） | -35.76 | 2.39 | 13.51 | | 资料来源：海通证券研究所 | | | | 分析 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [2][5][6] Core Insights - The company is a leading player in the domestic dairy farming industry, benefiting from a cyclical recovery in the market [4][6] - The company has a strong market position with a significant increase in market share from 19% to approximately 26% from 2019 to 2024 [6] - The company is expected to see a rebound in raw milk prices due to a reduction in supply and an increase in demand driven by government policies [6][9] - The company has a diversified product matrix, including organic and specialty milk products, which contribute to higher profit margins compared to regular milk [6][9] Financial Data and Forecasts - Revenue projections for the company are as follows: - 2023: 18,694 million CNY - 2024: 20,096 million CNY - 2025: 21,766 million CNY - 2026: 23,712 million CNY - 2027: 25,879 million CNY - Year-on-year growth rates for revenue are projected to be 3.6% in 2023, 7.5% in 2024, 8.3% in 2025, 8.9% in 2026, and 9.1% in 2027 [5][6] - Net profit is expected to turn positive by 2025, with projections of 679 million CNY in 2025, 1,748 million CNY in 2026, and 2,945 million CNY in 2027 [5][6] - The company’s gross margin is projected to improve from 23.9% in 2023 to 33.92% by 2027 [5][6] Industry Analysis - The domestic raw milk supply is characterized by a significant reduction in dairy cattle numbers, with a projected decline of 4.5% in Holstein cattle by 2024 [6][9] - The competitive landscape of the dairy industry is fragmented, with the top five companies holding a market share of approximately 19% [6][9] - The company benefits from a stable demand from its major shareholder, Yili Group, which accounts for about 95% of its raw milk revenue [6][9] Valuation Metrics - The company is expected to trade at a P/E ratio of 16-20 times by 2025, with a target price range of 3.00 to 3.75 HKD per share [6][9]

Investment Rating - The report assigns an "Outperform" rating for the company, indicating an expectation of relative performance exceeding the market benchmark by over 10% within six months following the report's release [5][19]. Core Insights - The company, Zhixing Technology, is a leading provider of autonomous driving solutions in China, leveraging advanced systems in software, hardware, and AI algorithms to deliver innovative products [6][7]. - The company is experiencing rapid growth in its autonomous driving business, with a significant increase in new orders and deliveries, reflecting a growing consumer acceptance of autonomous vehicles [6][8]. - The report highlights the company's strategic focus on AI-driven autonomous driving and its potential to create a closed-loop system that integrates AI development with hardware sales [7][9]. Financial Performance and Forecast - Revenue projections for Zhixing Technology are as follows: 2023: 1,216 million CNY, 2024: 1,248 million CNY, 2025E: 2,071 million CNY, 2026E: 3,220 million CNY, and 2027E: 4,182 million CNY, with year-on-year growth rates of -8%, 3%, 66%, 56%, and 30% respectively [6][12]. - The net profit forecast indicates losses in the initial years, with estimates of -195 million CNY in 2023, -288 million CNY in 2024, and a return to profitability with 23 million CNY in 2026 and 164 million CNY in 2027 [6][12]. - The report anticipates a significant increase in the gross margin from 7.28% in 2024 to 21.55% in 2027, driven by economies of scale as revenue grows [12][14]. Market Position and Competitive Advantage - Zhixing Technology has established a strong market presence with over 227,000 autonomous driving solutions delivered in 2024, marking a 75% increase from the previous year [6][8]. - The company has secured contracts with major OEMs, including Geely, Polestar, and Chery, enhancing its market credibility and expanding its operational footprint [6][8]. - The report emphasizes the company's technological edge, particularly in deploying advanced algorithms on low-power chips, positioning it as a pioneer in the industry [6][8]. Valuation and Investment Recommendation - The report employs a price-to-sales (P/S) valuation method, suggesting a valuation range of 18.60 to 24.18 HKD for 2025, based on a P/S ratio of 2.0 to 2.6 [6][12]. - The recommendation to "Outperform" is based on the anticipated growth trajectory of the autonomous driving market and the company's strategic initiatives to enhance its product offerings and market share [5][6].

Investment Rating - The report assigns an "Outperform" rating for the company, indicating an expected relative performance that exceeds the benchmark index by more than 10% over the next six months [10]. Core Insights - The company reported a revenue of 2.081 billion yuan for 2024, a decrease of 8.8% year-on-year, while the adjusted net profit increased by 61.1% to 170 million yuan. The fourth quarter of 2024 saw a revenue of 560 million yuan, down 10.6% [5][10]. - The company has introduced several AI recruitment applications, which have significantly improved user engagement and operational efficiency. The average monthly active users grew by 5.6% year-on-year, with a total registered user base of 106 million, reflecting an 11.1% increase [6][8]. - The company has initiated a special dividend plan, proposing a special dividend of 0.42 HKD per share, highlighting its commitment to returning value to shareholders [5]. Financial Performance - In 2024, the company achieved an adjusted operating profit of 229 million yuan, marking a 64.9% increase. The fourth quarter's adjusted operating profit was 50 million yuan, compared to 26 million yuan in the same quarter of the previous year [5][8]. - The company’s total liabilities stood at 786 million yuan, with cash and cash equivalents amounting to 1.211 billion yuan, indicating a strong liquidity position [10]. - The forecast for 2025-2027 suggests a gradual recovery in revenue, with expected revenues of 1.988 billion yuan in 2025 and 2.040 billion yuan in 2027, alongside a projected adjusted net profit of 230 million yuan in 2025 [9][10]. Market Position and Strategy - The company has successfully expanded its multi-hunting RCN platform, which has seen a growing demand for job positions, particularly in sectors like internet, energy, and manufacturing. By the end of 2024, 91% of the network had participated in collaborative delivery [7][8]. - The introduction of the AI interview system, Doris, has shown a consistent alignment with professional interviewers' judgments, maintaining a 95% accuracy rate, which enhances the recruitment process across various demographics [6][8].

Investment Rating - The report assigns an "Outperform" rating to the company [8]. Core Views - The company is expected to lead in high growth revenue in 2024, driven by the launch of the Journey 6 series, which will be adopted by over 20 automotive manufacturers and brands, covering a wide range of vehicle types from economy to luxury [9][12]. - The company aims to democratize advanced driving technology through three strategic directions: flagship high-level driving systems, mainstream pricing for urban NOA, and enhancing active safety features [9]. - The company has maintained a leading market share in the Chinese OEM ADAS market, exceeding 40%, and is positioned second in the OEM AD market with over 30% market share [11]. Financial Data and Forecast - Revenue is projected to grow significantly from 1,552 million in 2023 to 3,582 million in 2025, reflecting a year-on-year growth of 71% in 2023 and 54% in 2024 [10]. - The net profit is expected to improve from a loss of 6,739 million in 2023 to a profit of 755 million by 2027, with a notable increase of 135% in 2024 [10][12]. - The gross margin is forecasted to remain strong, with values around 77% for 2024 and beyond [10][15]. Business Segmentation - The automotive retail solutions segment is expected to generate revenue of 2,311.70 million in 2024, with a growth rate of 57% [15]. - Non-standard automotive insurance revenue is projected to decline slightly, while overall revenue is expected to grow at a compound annual growth rate of 54% from 2024 to 2027 [15]. Market Performance - The company's stock has shown significant absolute and relative growth, with a 261.7% increase over the last three months [7]. - The stock price as of April 1, 2025, was 6.40 HKD, with a market capitalization of approximately 70.886 billion HKD [4].

Investment Rating - The report maintains an "Outperform the Market" rating for the company [7]. Core Views - The new car business is under pressure, while the after-sales service and used car business are developing steadily [7]. - The company achieved a revenue of 168.1 billion yuan in 2024, a year-on-year decrease of 6.2%, and a net profit of 3.21 billion yuan, down 36% year-on-year [7]. - The company focuses on key urban areas to enhance performance resilience and has opened 37 AITO stores in collaboration with Seres for its new energy vehicle business [7]. Financial Data and Forecast - Total revenue is projected to be 183.52 billion yuan in 2023, with a slight decline of 0.3% year-on-year, followed by a forecasted revenue of 168.12 billion yuan in 2024, down 6% [6]. - Net profit is expected to decrease significantly to 3.21 billion yuan in 2024, a 36% decline, before recovering to 3.77 billion yuan in 2025, representing a 17% increase [6]. - The company’s gross margin is forecasted to improve from 6.35% in 2024 to 11.91% by 2027 [6]. - Earnings per share (EPS) are projected to be 1.35 yuan in 2024, increasing to 2.49 yuan by 2027 [6]. Business Segments - The new car sales volume in 2024 is expected to be 485,000 units, a decrease of 3.2% year-on-year, with revenue from new car sales at 125.3 billion yuan, down 10.6% [7]. - The used car business is showing robust growth, with sales expected to reach 226,000 units in 2024, a year-on-year increase of 37.9%, contributing 15.4 billion yuan in revenue [7]. - After-sales service revenue is projected to reach 22 billion yuan in 2024, a 9.6% increase, marking a historical high [7].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [4][6]. Core Insights - The company has demonstrated strong growth in product sales, achieving a total revenue of 2.124 billion RMB in 2024, with a year-on-year decline of 53.08%. However, commercial sales revenue increased by 24.88% to 2.002 billion RMB, and gross profit reached 1.835 billion RMB, reflecting a 16.53% increase in commercial sales gross profit [1][4]. - The company is building a core competitive advantage in tumor immunotherapy through its two main bispecific antibodies, Cardunilumab and Ivorisumab, which are undergoing extensive clinical exploration across over 40 indications. Notably, Ivorisumab has shown significant efficacy in treating advanced non-small cell lung cancer [2][4]. - The company is investing efficiently in research and development, with approximately 1.2 billion RMB allocated in 2024. This has resulted in the approval of three new drugs and the advancement of multiple clinical trials, including the first bispecific ADC drug entering clinical trials [3][4]. - The commercialization process is expected to accelerate, with key products entering the national medical insurance directory by the end of 2024, enhancing hospital access and coverage [3][4]. Financial Projections - The company is projected to achieve revenues of 3.82 billion RMB, 6.52 billion RMB, and 8.86 billion RMB from 2025 to 2027, with corresponding net profits of 107 million RMB, 1.064 billion RMB, and 2.083 billion RMB [4][5]. - The expected growth rates for revenue are 79.9% in 2025, 70.6% in 2026, and 35.9% in 2027, while net profit is anticipated to grow by 120.8% in 2025 and 896.9% in 2026 [5][4].